Venus Remedies Limited (IN:VENUSREM)
:VENUSREM
Want to see IN:VENUSREM full AI Analyst Report?
VENUSREM Stock Chart & Stats
₹782.25
-₹3.85(-1.26%)
At close: 4:00 PM EST
₹782.25
-₹3.85(-1.26%)
Day’s Range― - ―
52-Week Range₹417.65 - ₹1,484.95
Previous CloseN/A
Volume28.34K
Average Volume (3M)2.33K
Market Cap
₹18.90B
Enterprise Value₹16.93B
Total Cash (Recent Filing)₹2.36B
Total Debt (Recent Filing)₹143.80M
Price to Earnings (P/E)19.3
Beta0.76
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)52.61
Shares Outstanding13,366,988
10 Day Avg. Volume2,529
30 Day Avg. Volume2,330
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.65
Price to Sales (P/S)1.42
P/FCF Ratio9.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.9
Revenue Forecast (FY)₹828.20M
Bulls Say, Bears Say
Bulls Say
Improved Profitability & Cash GenerationThe marked profitability and cash generation improvement in 2026 indicates the business can generate excess cash to fund R&D, hospital portfolio expansion, or deleverage. Sustained higher operating income and cash flows enhance strategic optionality and resilience to industry cycles.
Conservative Balance Sheet / Low LeverageVery low leverage and steady equity growth (4.0B to 6.6B) give the company long-term financial flexibility. A conservative balance sheet supports capital spending, tender participation, and possible M&A without stressing liquidity, improving durability through downturns.
Strong Historical Free Cash Flow ConversionHigh historical free cash flow as a share of earnings shows the company can convert profits into spendable cash for reinvestment or balance-sheet strengthening. Persistent FCF supports long-term funding for product registrations and scale-up of hospital/exports.
Bears Say
Margin Volatility And Limited Margin TransparencyMaterial swings in gross margin reduce confidence in sustainable profitability. For a pharma business where pricing, raw material costs, and mix drive margins, fluctuating margins complicate cashflow forecasting and raise the risk that 2026 profit gains are not repeatable.
Uneven Cash Flow Conversion / Working-capital CyclicalityChoppy operating cash conversion implies working-capital swings or lumpy capex, which can strain liquidity and timing of investments. Over multiple periods, uneven cashflows make consistent reinvestment, dividend policy, or debt paydown planning more difficult.
Sustainability Risk Of 2026 Earnings SurgeManagement may have benefited from transitory factors in 2026. Without clearer margin drivers and steadier cash conversion, the earnings spike could reflect temporary gains rather than structural improvement, making future earnings and investment returns less predictable.
Venus Remedies Limited News
VENUSREM FAQ
What was Venus Remedies Limited’s price range in the past 12 months?
Venus Remedies Limited lowest stock price was ₹417.65 and its highest was ₹1484.95 in the past 12 months.
What is Venus Remedies Limited’s market cap?
Venus Remedies Limited’s market cap is ₹18.90B.
When is Venus Remedies Limited’s upcoming earnings report date?
Venus Remedies Limited’s upcoming earnings report date is Aug 18, 2026 which is in 74 days.
How were Venus Remedies Limited’s earnings last quarter?
Venus Remedies Limited released its earnings results on May 26, 2026. The company reported ₹35.53 earnings per share for the quarter, beating the consensus estimate of N/A by ₹35.53.
Is Venus Remedies Limited overvalued?
According to Wall Street analysts Venus Remedies Limited’s price is currently Overvalued.
Does Venus Remedies Limited pay dividends?
Venus Remedies Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Venus Remedies Limited dividends here
What is Venus Remedies Limited’s EPS estimate?
Venus Remedies Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venus Remedies Limited have?
Venus Remedies Limited has 13,366,988 shares outstanding.
What happened to Venus Remedies Limited’s price movement after its last earnings report?
Venus Remedies Limited reported an EPS of ₹35.53 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.339%.
Which hedge fund is a major shareholder of Venus Remedies Limited?
Currently, no hedge funds are holding shares in IN:VENUSREM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Venus Remedies Limited
Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin and wound care, stress reliever, urology, and vitamins/minerals/nutrients, as well as antimicrobial resistance products. It also provides disinfectants; and a portfolio of herbal products. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.
Technical Analysis
Indoco Remedies Limited
―
Ind-Swift Laboratories Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Syncom Formulation (India) Ltd.
―
Windlas Biotech Ltd.
―